While we are currently focusing our internal efforts on the development of personalized cancer vaccines, we have demonstrated that our proprietary ATLASTM antigen identification platform can be used across a broad range of disease applications and are seeking partners to realize the full potential of ATLAS in profiling patients' immune responses.
Specifically, the ATLAS platform can be used as a blood-based, non-invasive assay to detect the differing immune responses in patients successfully and unsuccessfully treated with cancer immunotherapies to inform patient selection in clinical trials and clinical practice – making sure the right patients get the right therapies.
- Checkmate Pharmaceuticals, Inc.: In December 2016, we announced a research collaboration with Checkmate to characterize patterns of T cell responses to tumor-associated antigens in advanced melanoma. The goal of the collaboration is to identify the specificity and characteristics of T cells associated with protective T cell responses to potentially optimize clinical development. ATLAS will be used to profile the T cell responses of patients enrolled in Checkmate's ongoing Phase 1b clinical trial of CMP-001 in combination with the checkpoint inhibitor pembrolizumab to a library of tumor-associated antigens common to patients with advanced melanoma. The T cell response signatures of those patients who respond to CMP-001 / pembrolizumab combination therapy will be compared to the signatures of those who do not respond, thereby potentially identifying antigens associated with positive or negative patient outcomes.
- Dana-Farber Cancer Institute: ATLAS’s advanced technology is also being leveraged to help identify patients that are most likely to respond, and very importantly, not respond, to immune checkpoint therapies. Due to the limited effectiveness of immune checkpoint therapy in most patients and the potential for significant adverse effects, it is imperative to identify the patients that will respond to these therapies. Results have demonstrated that patients that respond to immune checkpoint blockade therapy have a greater breadth of T cell activation than patients that do not respond to treatment. We are applying these results and expanding the utility of ATLAS as a prognostic tool to identify patients that could benefit from checkpoint inhibitor therapy in collaboration with DFCI.